Diversify Wealth Management LLC Acquires 3,572 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Diversify Wealth Management LLC boosted its stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) by 13.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 29,338 shares of the company's stock after buying an additional 3,572 shares during the period. Diversify Wealth Management LLC's holdings in Verona Pharma PLC American Depositary Share were worth $1,863,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Renaissance Technologies LLC acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the fourth quarter valued at approximately $720,000. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the first quarter valued at approximately $284,000. Wells Fargo & Company MN raised its holdings in shares of Verona Pharma PLC American Depositary Share by 27.2% in the fourth quarter. Wells Fargo & Company MN now owns 67,126 shares of the company's stock valued at $3,117,000 after purchasing an additional 14,362 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Verona Pharma PLC American Depositary Share by 366.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,486 shares of the company's stock valued at $720,000 after purchasing an additional 9,021 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Verona Pharma PLC American Depositary Share by 14.0% in the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company's stock valued at $117,000 after purchasing an additional 225 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on VRNA. Piper Sandler set a $160.00 price objective on shares of Verona Pharma PLC American Depositary Share and gave the company an "overweight" rating in a report on Monday, June 23rd. Jefferies Financial Group restated a "hold" rating and set a $107.00 target price (down from $140.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday. BTIG Research downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday. Cantor Fitzgerald boosted their target price on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. Finally, Truist Financial downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Wednesday. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Verona Pharma PLC American Depositary Share presently has an average rating of "Hold" and a consensus price target of $107.45.

Insider Activity at Verona Pharma PLC American Depositary Share

In other news, CEO David Zaccardelli sold 400,000 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total value of $4,560,000.00. Following the completion of the transaction, the chief executive officer owned 13,190,168 shares of the company's stock, valued at approximately $150,367,915.20. This represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Andrew Fisher sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $11.53, for a total transaction of $922,400.00. Following the completion of the transaction, the general counsel owned 359,999 shares of the company's stock, valued at approximately $4,150,788.47. This trade represents a 18.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,965,800 shares of company stock worth $20,056,881 over the last three months. 4.80% of the stock is owned by insiders.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of Verona Pharma PLC American Depositary Share stock traded down $0.02 during trading on Friday, reaching $104.83. The company's stock had a trading volume of 10,916,452 shares, compared to its average volume of 1,598,487. The business's 50-day moving average price is $83.89 and its 200-day moving average price is $67.67. The firm has a market cap of $8.92 billion, a PE ratio of -52.42 and a beta of 0.24. Verona Pharma PLC American Depositary Share has a 52 week low of $18.51 and a 52 week high of $104.99. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The business had revenue of $98.65 million during the quarter, compared to the consensus estimate of $41.47 million. Equities analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.